Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine add-on therapy for hospitalized patients with COVID-19 pneumonia
IRCT20200904048616N1Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus pneumonia comparing Fluoxetine + standard of care with Placebo + standard of care (2 arms). Primary endpoints: Blood oxygen saturation, Number of days of hospitalization and 3 more. Started May 2021; status: completed.
02
Drugs
fluoxetine
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on IRCT20200904048616N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200904048616N1.